Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase (NECT-FIELD)
This study has been completed.
Sponsor:
Drugs for Neglected Diseases
Collaborators:
Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), DRC
Swiss Tropical and Public Health Institute
Information provided by (Responsible Party):
Drugs for Neglected Diseases
ClinicalTrials.gov Identifier:
NCT00906880
First received: May 19, 2009
Last updated: May 30, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | January 2013 |
| Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |